Multaq adverse reactions
WebMULTAQ to report immediately symptoms suggesting hepatic injury (such as anorexia, nausea, vomiting, fever, malaise, fatigue, right upper quadrant pain, jaundice, dark urine, … Web23 mai 2024 · Summary. More frequently reported side effects include: abdominal pain, allergic dermatitis, diarrhea, eczema, nausea, pruritus, and skin rash. Continue reading …
Multaq adverse reactions
Did you know?
WebThe most common side effects of Multaq seen in clinical trials when compared to placebo include: Nausea Vomiting Loss of appetite Weakness Stomach pain Bradycardia (slow heartbeat) Unusual tiredness Indigestion Skin reactions such as rash and itching Multaq can sometimes cause more serious side effects, including: Web1 apr. 2024 · Multaq; Descriptions. ... Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Webpatients treated with MULTAQ in the postmarketing setting [see Adverse Reactions (6.2)]. Onset of dyspnea or non-productive cough may be related to pulmonary toxicity and patients should be carefully evaluated clinically. If pulmonary toxicity is confirmed, MULTAQ should be discontinued. WebWhat is Multaq? Multaq is a medicine that contains the active substance dronedarone. It is available as white, oblong tablets (400 mg). ... The most frequent adverse reactions observed with dronedarone 400 mg twice daily in the 5 studies . were diarrhoea, nausea and vomiting, fatigue and asthenia. ...
WebThe most common side effects when taking MULTAQ include stomach problems such as diarrhea, nausea, vomiting, stomach area pain, and indigestion; feeling tired and weak; skin problems such as redness, rash, and itching. Tell your doctor about any side effect that bothers you or that does not go away. Web11 ian. 2024 · For further information call emc accessibility on 0800 198 5000 . The product code (s) for this leaflet is: PLGB 04425/0833. Print patient leaflet as text only. Print patient leaflet in large text. Expand All. Multaq 400mg tablets. Package leaflet: Information for the patient. 1. What MULTAQ is and what it is used for.
WebStatins: Avoid simvastatin doses greater than 10 mg daily. Follow statin label recommendations for use with CYP 3A and P-gP inhibitors such as MULTAQ; Adverse Reactions. In studies, the most common adverse reactions observed with MULTAQ were diarrhea, nausea, abdominal pain, vomiting, and asthenia.
Web6 iun. 2024 · The most frequent adverse reactions observed with MULTAQ 400 mg twice daily in the 5 studies were diarrhea, nausea, abdominal pain, vomiting, and asthenia. … millbrook cavan soccerWebOnly 1 (0.4%) of the 234 patients was identified as having a probable allergic reaction to amiodarone (score of 6 on the Naranjo adverse drug reaction probability scale). One additional patient receiving intravenous amiodarone experienced a rash that was determined to be caused by an antibiotic. next auth profile callbackWebIn studies, the most common adverse reactions observed with MULTAQ were diarrhea, nausea, abdominal pain, vomiting, and asthenia. Click here for full Prescribing … next auth schemaWebMULTAQ to report immediately symptoms suggesting hepatic injury (such as anorexia, nausea, vomiting, fever, malaise, fatigue, right upper quadrant pain, jaundice, dark urine, … millbrook cemetery manitobaWebWhat are possible serious side effects from taking MULTAQ? MULTAQ may cause serious side effects including slowed heartbeat, inflammation of the lungs (including scarring and … millbrook ccWebIn studies, the most common adverse reactions observed with MULTAQ were diarrhea, nausea, abdominal pain, vomiting, and asthenia. Click here for full Prescribing … millbrook cavan libraryWebMarket Adverse Drug Reactions, Renal). Monitoring and Laboratory Tests It is recommended to closely monitor patients taking MULTAQ including ECG at least every 6 months. If patients treated with MULTAQ develop permanent AF, treatment with MULTAQ should be discontinued. Management of plasma creatinine increase next auth react